Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0909 BTS40 Leung podcast
BioCentury & Getty Images

Back to School 2020

Qiming’s Leung: COVID-19 response displays the deep networks of China’s biotech ecosystem: a BioCentury audio interview

VC Nisa Leung describes the coordinated response among Chinese biotechs and healthcare professionals in COVID-19

VC Nisa Leung describes the coordinated response among Chinese biotechs and healthcare professionals in COVID-19.

Sep 10, 2020 | 2:06 AM GMT

The picture Nisa Leung, managing director of Qiming Venture Partners, paints of the response among Chinese biotechs to COVID-19 is one that underscores how the local ecosystem has matured from a “budding” one to a highly dynamic, integrated scene, with biotech CEOs and healthcare providers in close communication.

On an audio interview for BioCentury’s Back to School — part of a series of interviews with key industry leaders — Leung expanded on the difference in China between this outbreak and what she witnessed early in her career with the SARS 2003 response (see Cover Story: “Back to School 2020”).

“Back then,” said Leung, “China didn’t have the ability to develop their own diagnostic. They had to send the virus strain overseas to develop — let alone vaccines and whatnot,” she said. “This time around, we’re able to see that everybody stepped in.”

For example,

Read the full 2000 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE